84例肺血栓栓塞症的抗凝治疗分析

Analysis on anticoagulant therapy of 84 patients with pulmonary thromboembolism.

目的探讨低分子肝素(lowmolecularweightheparin,LMWH)与普通肝素(unfractionatalheparin,UFH)在治疗肺血栓栓塞症(pulmonarythromboembolism,PTE)的疗效和安全性差异。方法将收治的84例肺血栓栓塞症患者,随机分成两组,42例为治疗组,42例为对照组,治疗组应用低分子肝素抗凝治疗,对照组应用普通肝素抗凝治疗,观察其疗效及副作用。结果治疗组总有效率90.5%,对照组总有效率69.1%,副作用出现率治疗组为7.1%,对照组为14.3%。结论低分子肝素和普通肝素均为有效的抗凝药物,综合副作用和治疗效果考虑,低分子肝素更适合于临床。

Objective To compare the efficiency and safety between low molecular weight heparin and unfractionated heparin in treating patients with pulmonary thromboembolism （PTE） . Methods The total of 84 patients with PTE were divided into low molecular weight heparin group （42 patients） and unfractionated heparin group （42 patients） at random, and then the therapeutic effect and side - effect were observed. Results The overall respond rate was better in low molecular weight heparin group than that in the unfraetionated heparin group （90. 5% to 69. 1% ）, and the side effect was lower in the low molecular weight heparin group than that in the urffractionated heparin group （7.1% to 14. 3% ）. Conclusion The low molecular weight heparin and unfractionated heparin are both efficient anticoagulant drug in treating pulmonary thromboembolism, but low molecular weimar heparin is safer and better.